The HIV Ag/Ab test is a combination blood test that looks for two things at once: pieces of the virus itself (a protein called p24) and the antibodies your immune system makes in response to HIV. By hunting for both targets simultaneously, this type of test can identify an infection roughly a week earlier than older tests that looked for antibodies alone, shrinking the detection window to about 11 to 14 days after exposure.1PubMed Central. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution It is now the first step in the standard laboratory testing sequence recommended for HIV diagnosis in the United States and many other countries, and understanding what it does and does not catch matters for anyone getting tested.
Two Targets, One Test
When HIV enters your body, it hijacks cells and begins replicating rapidly. Within the first one to two weeks, the virus produces large quantities of a structural protein called p24, which forms the shell around the virus’s genetic material. This protein spills into the bloodstream and becomes detectable before your immune system has had time to mount an antibody response.2PubMed Central. p24 revisited: a landscape review of antigen detection for early HIV diagnosis Older-generation HIV tests waited for antibodies to appear, which could take three weeks or longer. The Ag/Ab combination test catches that earlier phase by also reacting to p24 antigen in the sample.
Antibodies, meanwhile, remain the more durable marker. Once your immune system recognizes HIV and produces antibodies against it, those antibodies persist essentially for life. So the p24 component of the test covers the brief early window when antibodies have not yet appeared, and the antibody component covers everything from seroconversion onward. Together, the two targets leave very little time unaccounted for.
Why the Window Period Matters So Much
The “window period” is the gap between when a person contracts HIV and when a test can reliably detect it. For third-generation tests, which detected only antibodies (including IgM), the median window was about 22 days. Fourth-generation Ag/Ab tests shortened that to a median of roughly 18 days.3PubMed. Probability of a false-negative HIV antibody test result during the window period: a tool for pre- and post-test counselling Head-to-head comparisons on seroconversion panels have shown the improvement more starkly: fourth-generation assays detected infection an average of about five to eight days sooner than third-generation tests.4PubMed Central. Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays
Those extra days of detection carry real consequences. People in the acute phase of HIV, before antibodies develop, often have extremely high viral loads and are highly infectious. Identifying and treating someone during that acute phase reduces the chance they unknowingly pass the virus to others and avoids irreversible damage to the immune system that happens when the infection goes unchecked.5PubMed Central. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review Starting antiretroviral therapy early drives the viral load down quickly, which both protects the individual’s health and limits onward transmission.6PubMed. Benefits of antiretroviral therapy initiation during acute HIV infection
How Laboratory Ag/Ab Tests Actually Run
In most clinical laboratories, the Ag/Ab test uses a technique called chemiluminescent immunoassay (often abbreviated CMIA or CLIA). A blood sample, typically drawn from a vein, is mixed with reagents designed to bind to both p24 antigen and HIV-1/HIV-2 antibodies. If either target is present, the reagents trigger a light signal that the instrument measures. The ratio of that signal to a predetermined cutoff value determines whether the result is reactive (positive screening) or nonreactive (negative).
These laboratory-based assays are remarkably accurate. One large real-world evaluation of a fourth-generation test found sensitivity of 100% and specificity above 99.8%.7The Journal of Applied Laboratory Medicine. Real-World Clinical Performance Evaluation of a Fourth-Generation HIV Antigen/Antibody Differentiation Test A newer screening assay showed similarly high performance, with 100% sensitivity for both chronic and primary HIV-1 infection and specificity above 99.9%.8PubMed Central. Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2 That said, no screening test is perfect on its own, which is why a reactive result always triggers follow-up testing before a diagnosis is made.
The Recommended Testing Algorithm
In the United States, the CDC recommends a specific sequence of tests rather than relying on a single result. The process starts with the fourth-generation Ag/Ab combination immunoassay. If that initial screen is nonreactive, the person is considered HIV-negative (assuming they are outside the window period). If the screen is reactive, the lab moves to a second test: an antibody differentiation assay that distinguishes HIV-1 antibodies from HIV-2 antibodies.9CDC Stacks. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations
Here is where things get interesting. If the differentiation test confirms HIV-1 or HIV-2 antibodies, the diagnosis is established. But if the differentiation test comes back negative or indeterminate while the initial Ag/Ab screen was reactive, the lab performs a nucleic acid test (NAT), which looks directly for HIV’s genetic material. A positive NAT in that scenario indicates acute HIV infection: the person has the virus and has p24 antigen in their blood, but has not yet produced detectable antibodies. This three-step algorithm is what makes the Ag/Ab test so useful as a front door. It catches both established and very early infections, and the follow-up steps sort out which category the person falls into.
False Positives and What Causes Them
A reactive Ag/Ab screening result does not automatically mean a person has HIV. False positives happen, and certain conditions make them more likely. Studies have consistently linked false-positive results to pregnancy, malignancy, older age, and various chronic illnesses.10PubMed Central. HIV infection in Xi’an, China: epidemic characterization, risk factors to false positives and potential utility of the sample-to-cutoff index to identify true positives using Architect HIV Ag/Ab combo A more recent analysis found false positives associated with at least 18 disease categories, with digestive system disorders being the most common, along with malignant tumors, pregnancy, and cerebral infarction.11Journal of Clinical Virology. False-positive results in fourth-generation HIV screening tests: Prevalence and associated factors in Sichuan, a high HIV burden province of China
This is why the testing algorithm exists. A screening test is designed to be very sensitive, to avoid missing true infections, and that sensitivity comes at the cost of occasionally flagging samples that are not truly positive. The confirmatory steps (the antibody differentiation assay and, if needed, the NAT) are designed to sort true infections from false alarms. If you receive a preliminary reactive result, the confirmatory testing that follows is not optional or redundant; it is the part that actually establishes or rules out a diagnosis.
Laboratories can also use the signal-to-cutoff ratio from the initial screening to get a rough sense of how likely a reactive result is to be a true positive. Research has shown that higher signal-to-cutoff values correlate strongly with confirmed infection, while values just barely above the cutoff are more likely to be false positives.12PubMed Central. Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy This information helps clinicians prioritize how quickly to initiate follow-up, though it never replaces confirmatory testing.
When the Test Can Miss an Infection
False negatives are rarer than false positives with modern laboratory assays, but they do occur. The most obvious scenario is testing too soon after exposure, before even p24 antigen has risen to detectable levels. In the first two weeks after infection, the amount of virus in the blood may simply be too low for the test to pick up.
A subtler cause of missed infections involves people who are already taking antiretroviral medications for prevention, known as pre-exposure prophylaxis or PrEP. PrEP partially suppresses the virus if someone does become infected, which can delay the appearance of detectable p24 antigen and antibodies by about a week.13PubMed. Effect of HIV pre-exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post-PrEP deferral period In those cases, NAT (which detects the virus’s genetic material directly) was the first test to flag the infection roughly 90% of the time. This is one reason why people on PrEP are typically tested regularly with a combination of methods.
Very low viral loads can also cause the test to miss an early infection. In one evaluation in Southern Africa, a fourth-generation assay detected 10 of 12 acute infections, and the two it missed both had viral loads below 400 copies per milliliter, with one of those patients already on antiretroviral therapy.14Journal of Clinical Virology. Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa The lesson: antiretrovirals in the system, whether for treatment or prevention, can suppress viral markers enough to delay detection.
Rapid and Point-of-Care Versions
Not every Ag/Ab test requires a laboratory. Fourth-generation rapid diagnostic tests (RDTs) exist that can deliver results in under 30 minutes using a finger-prick blood sample. These are critical in settings where laboratory infrastructure is limited or where people may not return for results. However, the performance gap between rapid and laboratory-based versions is real, especially for catching acute infections.
A recent study of two fourth-generation rapid tests found that their overall sensitivity was around 94 to 97% across all stages of infection, but when looking only at pre-seroconversion samples (the acute phase where only p24 antigen is present), sensitivity dropped to about 67 to 82%.15Journal of Clinical Virology. Fourth generation HIV rapid diagnostic test: Adequate sensitivity in HIV primary infection settings? Neither rapid test picked up infections within the first two weeks. Between two and three weeks post-infection, one of the two tests caught about 91% of cases, while the other caught about 73%. After three weeks, both detected all infections.
A systematic review and meta-analysis of WHO-prequalified rapid Ag/Ab tests painted a similar picture. The pooled sensitivity for detecting acute infection overall was about 94%, but the p24 antigen component alone had a pooled sensitivity of roughly 75 to 76% depending on the reference standard used.16medRxiv. Should WHO-prequalified antigen-antibody fourth-generation rapid diagnostic tests be used to detect acute HIV infection? A systematic review and meta-analysis of diagnostic performance In other words, rapid tests are good at confirming established infections but miss a meaningful fraction of very early ones. If you have had a recent high-risk exposure and get a negative result on a rapid Ag/Ab test, a laboratory-based test or a NAT may still be warranted.
Not All Assays Are Created Equal
Several FDA-approved fourth-generation assays are in wide use, and they do differ in how sensitively they detect p24 antigen and how quickly they flag early infections. A head-to-head comparison of three major platforms found that the limit of detection for p24 varied considerably: one platform detected p24 at concentrations as low as 0.19 IU/mL, while another needed concentrations above 1.77 IU/mL before it registered as reactive. The most sensitive platforms also detected seroconversion samples a few days earlier.17Journal of Clinical Virology. ARCHITECT HIV Ag/Ab Combo assay: Correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates For established infections, all of the assays performed well, but those few days of difference in early detection can matter in acute-infection settings.
HIV is also genetically diverse, with multiple subtypes circulating around the world. Fortunately, the p24 protein is relatively conserved across these subtypes, and testing has shown that the relationship between p24 sensitivity and viral load remains consistent across genetically diverse strains of HIV-1 group M, which accounts for the vast majority of infections worldwide.17Journal of Clinical Virology. ARCHITECT HIV Ag/Ab Combo assay: Correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates The newer Bio-Rad Access assay showed a consistent limit of detection across 11 analyzed subtypes.8PubMed Central. Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2 This is reassuring: wherever you are in the world and whatever strain of HIV is circulating locally, the test is designed to detect it.
Why These Tests Do Not Work for Newborns
One important exception to the usefulness of Ag/Ab tests involves infants born to mothers living with HIV. During pregnancy, a mother’s antibodies cross the placenta and enter the baby’s bloodstream. Those maternal HIV antibodies can persist in the infant for up to 18 months, meaning an Ag/Ab test on a newborn or young infant could come back reactive even if the child is not actually infected.18NIH Clinicalinfo / Perinatal HIV Clinical Guidelines. Diagnosis of HIV Infection in Infants and Children The p24 antigen component is also less sensitive in the first months of life than a nucleic acid test. For this reason, the diagnosis of HIV in infants with known perinatal exposure relies on virologic testing (NAT) rather than any antibody-based or combination assay. Ag/Ab tests become useful for this population only after the child is old enough for maternal antibodies to have cleared.
Fifth-Generation Tests and What They Add
Fifth-generation assays take the concept one step further by reporting the p24 antigen result and the antibody result separately, rather than lumping them into a single reactive or nonreactive output. This distinction matters because it helps identify acute infection right at the screening step: if the antigen signal is positive but the antibody signal is negative, the lab knows it is likely dealing with very recent infection. Fourth-generation tests flag the sample as reactive without specifying which component triggered the result, so the differentiation has to wait for follow-up testing.
Research comparing fourth- and fifth-generation assays has shown that the antigen index from fifth-generation tests can differentiate true acute infections from false positives with high accuracy.12PubMed Central. Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy This has practical implications for how quickly treatment can begin. In a system where acute infection is identified at the very first step, a clinician might start antiretroviral therapy the same day rather than waiting days for confirmatory results to return. The tradeoff is that fifth-generation platforms are not yet as widely deployed as fourth-generation ones, particularly in lower-resource settings.
Cost-Effectiveness in the Real World
Switching from third-generation to fourth-generation testing costs more per test, and the added value shows up primarily in settings with higher rates of new infections. One modeling study estimated that in a population with 1% HIV prevalence, screening 1.5 million people with a fourth-generation test instead of a third-generation one would detect about 266 additional cases, prevent 26 transmissions, and gain roughly 395 quality-adjusted life years, though at a high incremental cost per additional case detected.19PubMed. Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States The economics look better when the testing is targeted. Annual screening of men who have sex with men and people who inject drugs using a fourth-generation test costs less than $10,000 per quality-adjusted life year gained, and screening every six months still stays under $20,000.20PLOS ONE. HIV Screening via Fourth-Generation Immunoassay or Nucleic Acid Amplification Test in the United States: A Cost-Effectiveness Analysis Both of those figures fall well within the range that health economists consider a good use of resources.
The cost argument is not just about the test itself but about the downstream consequences. Every acute infection identified early is an infection treated before the immune system is severely damaged and before the person unknowingly transmits HIV during the period of highest infectiousness. The math favors combination testing most strongly in clinical settings that serve populations with ongoing transmission.
Getting Your Results
One practical concern that comes up is how results are communicated. A laboratory-based Ag/Ab test typically takes one to several days to return results, depending on the facility. If the initial screen is reactive and confirmatory testing is needed, the timeline stretches further. Clinicians and patients have different preferences about how to handle this waiting period. Research exploring these preferences found that for some patients, receiving a preliminary result by phone followed by an in-person appointment can reduce anxiety and speed up connection to HIV care, while others prefer to receive all results face-to-face.21PubMed Central. Requesting HIV Results Be Conveyed in-Person: Perspectives of Clinicians and People Recently Diagnosed with HIV If you are getting tested, it is worth asking your clinic about their protocol for result delivery so you know what to expect.
For people using rapid Ag/Ab tests at a clinic or community testing site, the wait is much shorter, often under 30 minutes. But as discussed, a reactive rapid result still needs laboratory confirmation, and a negative rapid result during a high-risk window may still warrant follow-up laboratory testing. The rapid version is a useful first look, not the final word.